EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome



Evaluation of mycophenolate mofetil or tacrolimus in children with steroid sensitive but frequently relapsing or steroid-dependent nephrotic syndrome



Nephrology 21(1): 21-27



Approximately 30-40% of children with steroid sensitive nephrotic syndrome have frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS). Mycophenolate mofetil (MMF) and tacrolimus (TAC) are often alternative treatment choices for these patients. A single-center prospective study was conducted to compare the efficacy of MMF or TAC in reducing relapses and maintaining remission in children with FRNS or SDNS. Of the 72 recruited patients, either MMF (20∼30 mg/kg/d, n = 34) or TAC (0.05∼0.15 mg/kg/d, n = 38) was administered for 12 months. The mean 6-month relapse rates decreased from 2.56 episodes before therapy to 0.76 episodes in the first 6 months after therapy (c(2) = 44.362, p < 0.001) and 0.67 in the next 6 months (c(2) = 37.817, p < 0.001) in the MMF group. In the TAC group, the mean 6-month relapse rates decreased from 2.39 episodes before therapy to 0.41 episodes in the first 6 months after therapy (c(2) = 62.242, p < 0.001) and 0.42 in next 6 months (c(2) = 67.482, p < 0.001). No significant difference in the relapse rate was found between the groups (before therapy, c(2) = 0.902, p = 0.637; first 6 months, c(2) = 5.358, p = 0.147; second 6 months, c(2) = 4.089, p = 0.252). And there was also no significant difference in cumulative sustained remission and the incidence of adverse events between two groups. In combination with low-dose steroids, MMF or TAC presented similar efficacy in maintaining remission in children with FRNS/SDNS in the present study. Therapy with MMF or TAC is a promising strategy with a moderate risk of side effects in children who are steroid sensitive but have FRNS/SDNS.

(PDF emailed within 0-6 h: $19.90)

Accession: 057814557

Download citation: RISBibTeXText

PMID: 26697959

DOI: 10.1111/nep.12537



Related references

Mycophenolate mofetil in children with steroid-dependent and/or frequently relapsing nephrotic syndrome. Annals of Saudi Medicine 25(5): 380-384, 2005

Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatric Nephrology 20(10): 1376-1381, 2005

Mycophenolate Sodium for Children with Frequently Relapsing or Steroid Dependent Nephrotic Syndrome. Indian Pediatrics 54(10): 885-886, 2018

Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07). Bmc Nephrology 19(1): 302-302, 2018

The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent/Frequent Relapsing Nephrotic Syndrome. Nephron 132(4): 327-334, 2016

Should mycophenolate mofetil be administered prior to cyclosporine A as a steroid-sparing agent to children with steroid-dependent nephrotic syndrome?. Pediatric Nephrology: -, 2018

Multicenter trial of mycophenolate mofetil in children with steroid dependent or frequent relapsing nephrotic syndrome Report of the Southwest Pediatric Nephrology Study Group. Journal of the American Society of Nephrology 14(Abstracts Issue): 751A, November, 2003

Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing. Nephrology 20(1): 18-24, 2015

Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. Clinical Kidney Journal 10(5): 632-638, 2017

Immunosuppressive therapy in children with steroid-resistant, frequently-relapsing, and steroid-dependent idiopathic nephrotic syndrome: a single center experience. Electronic Physician 8(2): 2039-2047, 2016

Mycophenolate mofetil is inferior to tacrolimus in sustaining remission in children with idiopathic steroid-resistant nephrotic syndrome. Kidney International 92(1): 248-257, 2017

Ciclosporine csa vs cyclophosphamide cyc in children with steroid dependent frequently relapsing nephrotic syndrome sd fr ns evaluation of growth. Journal of Autoimmunity 5(SUPPL A): XL, 1992

Renal biopsy bx in frequently relapsing steroid dependent steroid resistant nephrotic syndrome frns sdns srns in children two north american surveys. Journal of the American Society of Nephrology 3(3): 319, 1992

Mycophenolate mofetil allows steroid withdrawal in steroid dependent nephrotic syndrome. Pediatric Research 51(4 Part 2): 429A, April, 2002

Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome. American Journal of Kidney Diseases 42(6): 1114-1120, 2003